Shortened treatment regimens versus the standard regimen for drug‐sensitive pulmonary tuberculosis
Referencias
Additional references
Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307(5707):223‐7.
Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double‐blind, randomised, controlled phase II trial. Lancet 2009;373(9670):1183‐9.
D'Ambrosio L, Centis R, Sotgiu G, Pontali E, Spanevello A, Migliori GB. New anti‐tuberculosis drugs and regimens: 2015 update. ERJ Open Research 2015;1(1):00010‐2015.
Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA‐824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open‐label, partly randomised trial in patients with drug‐susceptible or drug‐resistant pulmonary tuberculosis. Lancet 2015;385(9979):1738‐47.
Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug‐resistant tuberculosis: long‐term outcome, tolerability, and effect on emergence of drug resistance. Antimicrobial Agents and Chemotherapy 2012;56(6):3271‐6.
Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug‐resistant tuberculosis and culture conversion with bedaquiline. New England Journal of Medicine 2014;371(8):723‐32.
Gelband H. Regimens of less than six months for treating tuberculosis. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD001362]
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four‐month moxifloxacin‐based regimens for drug‐sensitive tuberculosis. New England Journal of Medicine 2014;371(17):1577‐87.
Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinburgh, Scotland) 2010;90(3):162‐7.
Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet. Infectious Diseases 2003;3(7):432‐42.
Gler MT, Skripconoka V, Sanchez‐Garavito E, Xiao H, Cabrera‐Rivero JL, Vargas‐Vasquez DE, et al. Delamanid for multidrug‐resistant pulmonary tuberculosis. New England Journal of Medicine 2012;366(23):2151‐60.
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 12 November 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Haverkamp W, Kruesmann F, Fritsch A, van Veenhuyzen D, Arvis P. Update on the cardiac safety of moxifloxacin. Current Drug Safety 2012;7(2):149‐63. [PUBMED: 22873499]
Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P, et al. Randomized clinical trial of thrice‐weekly 4‐month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 2013;8(7):e67030.
Jindani A, Harrison TS, Nunn AJ, Phillips PPJ, Churchyard GJ, Charalambous S, et al. High‐dose rifapentine with moxifloxacin for pulmonary tuberculosis. New England Journal of Medicine 2014;371(17):1599‐608.
Kerantzas CA, Jacobs WR. Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application. mBio 2017;8(2):e01586‐16.
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Lessem E, Cox H, Daniels C, Furin J, McKenna L, Mitnick CD, et al. Access to new medications for the treatment of drug‐resistant tuberculosis: patient, provider and community perspectives. International Journal of Infectious Diseases 2015;32:56‐60.
Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Current Opinion in Pulmonary Medicine 2010;16(3):186‐93.
Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375(9731):2100‐9.
Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC‐67683, a nitro‐dihydro‐imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Medicine 2006;3(11):e466.
Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four‐month gatifloxacin‐containing regimen for treating tuberculosis. New England Journal of Medicine 2014;371(17):1588‐98.
Mitchison DA. The action of antituberculosis drugs in short‐course chemotherapy. Tubercle 1985;66(3):219‐25.
Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67(14):2077‐99.
Munsiff SS, Kambili C, Ahuja SD. Rifapentine for the treatment of pulmonary tuberculosis. Clinical Infectious Diseases 2006;43(11):1468‐75.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. Journal of Antimicrobial Chemotherapy 2002;49(4):593‐6.
Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 2008;12(2):128‐38.
Sacksteder KA, Protopopova M, Barry CE, Andries K, Nacy CA. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiology 2012;7(7):823‐37.
Schluger NW. Fluoroquinolones in the treatment of tuberculosis: which is best?. American Journal of Respiratory and Critical Care Medicine 2013;188(7):768‐9.
Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JWC, Anger HA, Caminero JA, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR‐TB and XDR‐TB: systematic review and meta‐analysis. European Respiratory Journal 2012;40(6):1430‐42.
Temple ME, Nahata MC. Rifapentine: its role in the treatment of tuberculosis. Annals of Pharmacotherapy 1999;33(11):1203‐10.
Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, et al. Pharmacokinetics and whole‐blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU‐100480 in healthy volunteers. Journal of Infectious Diseases 2010;202(5):745‐51.
World Health Organization. Guidelines for treatment of tuberculosis. 4th edition. 2010. WHO/HTM/TB/2009.420. www.who.int/tb/publications/2010/9789241547833/en/ (accessed 1 July 2017).
World Health Organization. The End TB Strategy. Global strategy and targets for tuberculosis prevention, care and control after 2015. WHO/HTM/TB/2015.19. www.who.int/tb/post2015_strategy/en/ (accessed 1 August 2017).
World Health Organization. Global Tuberculosis Report 2017. www.who.int/tb/publications/global_report/en/ (accessed 12 November 2017).
World Health Organization. Fact sheet on tuberculosis. October 2017. www.who.int/mediacentre/factsheets/fs104/en/ (accessed 12 November 2017).
World Health Organization. Bending the curve ‐ ending TB: annual report 2017. apps.who.int/iris/bitstream/10665/254762/1/978929022584‐eng.pdf. WHO Regional Office for South‐East Asia, (accessed 12 July 2017).
Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, et al. Promising antituberculosis activity of the oxazolidinone PNU‐100480 relative to that of linezolid in a murine model. Antimicrobial Agents and Chemotherapy 2009;53(4):1314‐9.
Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug‐sensitive). Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD004795.pub4]
Zumla AI, Gillespie SH, Hoelscher M, Philips PPJ, Cole ST, Abubakar I, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet. Infectious Diseases 2014;14(4):327‐40.
